There is one clinical trial.
The purpose of this study is to document the feasibility and tolerability of low dose thoracic radiotherapy in patients with WHO level 5 COVID 19 infections.
Description: Feasibility to recruit to the study.Measure: Feasibility of Recruitment Time: 6 months
Description: Proportion of patients with no decline in PaO2/FiO2 ratio (P/F Ratio) at 48 hours after each fraction of radiotherapyMeasure: Tolerability of Low dose Radiotherapy Time: 48 hours
Description: The number of patients who withdraw from the studyMeasure: Withdrawal Time: 6 months
Description: The number of Grade 4 or higher CTCAE v5 (apart from asymptomatic lymphopenia) adverse events reportedMeasure: Adverse events Time: 1 month
Description: Ability to perform lymphocyte subset, IL-6, and IL-10 analysis at baseline and 7 days post last fraction of radiotherapyMeasure: Feasibility of biochemical analysis Time: 1 week
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports